Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | RBBP9 | O75884 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1896858 | 0.87 | LMNA (0.53) | LMNAFFAR1FFAR4NPSR1TRPM8 | |
| SCHEMBL27611972 | 0.86 | POLB (0.49) | LMNANPSR1ALDH1A1GLAMEN1 | |
| SCHEMBL6791636 | 0.84 | LMNA (0.41) | LMNAFFAR1FFAR4TRPM8NPC1 | |
| SCHEMBL7261472 | 0.84 | LMNA (0.43) | LMNAFFAR1FFAR4TRPM8NPC1 | |
| SCHEMBL11482412 | 0.84 | ALDH1A1 (0.41) | LMNATRPM8NPC1RAB9AALDH1A1 | |
| SCHEMBL2772989 | 0.84 | LMNA (0.51) | LMNAFFAR1FFAR4NPSR1TRPM8 | |
| SCHEMBL6054457 | 0.84 | LMNA (0.45) | LMNAFFAR1FFAR4NPSR1TRPM8 | |
| SCHEMBL2772986 | 0.84 | LMNA (0.51) | LMNAFFAR1FFAR4NPSR1TRPM8 | |
| SCHEMBL27930079 | 0.83 | LMNA (0.50) | LMNAFFAR1FFAR4NPSR1TRPM8 | |
| SCHEMBL1431733 | 0.81 | LMNA (0.41) | LMNACDK2GSK3BGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740484-A1 | 5-(PYRIMIDIN-4-YL)THIAZOL-2-YL UREA DERIVATIVES AS THERAPEUTIC AGENTS | AUCENTRA HOLDINGS PTY LTD (AU) | 2020-11-25 | — | — | EP | claimed |
| CN-103228633-A | Heterocyclic compounds as DGAT1 inhibitors | PIRAMAL LIFE SCIENCES LTD | 2013-07-31 | — | — | CN | disclosed |
| CN-101953297-B | Method for promoting growth of kohlrabi free microspore embryos | UNIV NORTHWEST A&F | 2012-09-05 | — | — | CN | disclosed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| CN-101953297-A | Method for promoting growth of kohlrabi free microspore embryos | UNIV NORTHWEST A&F | 2011-01-26 | — | — | CN | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG | 2010-03-25 | — | — | US | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
| EP-1989201-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007095588-A1 | PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075965-A1 | PI3 KINASE INHIBITORS AND METHODS OF THEIR USE | PIK3CA, PIK3CD, PIK3CB | LMNA 3610/4885FFAR1 988/4885FFAR4 1304/4885 |
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | LMNA 3030/4885FFAR1 2097/4885FFAR4 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.